Heart failure & cardiomyopathiesSecondary analysis
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy
- Secondary analysis of the HELIOS-B randomised trial
- subgroup analysis by baseline tafamidis use
- tafamidis use stratified
Authors' conclusion
Treatment effect estimates for vutrisiran on clinical outcomes were consistent across baseline tafamidis strata, with no statistically significant interaction according to baseline tafamidis use, with reduced effect size noted in those receiving baseline stabilizers in comparison to monotherapy.
Study context
- Population
- Patients with ATTR-CM (transthyretin amyloidosis with cardiomyopathy), by baseline tafamidis use259 (40%) on tafamidis
- Participants
- 654 patients
- Comparison
- Vutrisiran vs placebo, by baseline tafamidis use
- Primary endpoint
- All-cause mortality and recurrent CV events
Primary result
As reported in the abstract
All-cause mortality and recurrent CV events, by baseline tafamidis use
Vutrisiran vs PlaceboRate ratio (95% CI)
with tafamidis
0.79(0.51–1.21)
without tafamidis
0.67(0.49–0.93)
Secondary outcomes
All-cause mortality, CV events, outpatient worsening HF, by baseline tafamidis use
- Similar patterns; effects numerically smaller with tafamidis
- all interaction P > 0.20
6-minute walk distance, by baseline tafamidis use
- Vutrisiran preserved 6-minute walk distance in both strata
- interaction P = 0.24
KCCQ-OSS, by baseline tafamidis use
- Improvement appeared attenuated with baseline tafamidis
Original publication
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. Published 30 August 2026. doi:10.1016/j.jacc.2026.07.022
Summarised from the published abstract; every number is checked against it